TY - JOUR
T1 - Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries
AU - Mailankody, Sharada
AU - Kumar, Venkatesan Sampath
AU - Khan, Shah Alam
AU - Banavali, Shripad D.
AU - Bajpai, Jyoti
N1 - Funding Information:
We are grateful to the patients, their families, and investigators especially those working within the challenges of LMIC and trying to provide solutions. We would like to acknowledge Mr. Mohammed Asif M. for helping with the illustrations.
Publisher Copyright:
© 2021 Wiley Periodicals LLC
PY - 2022/3
Y1 - 2022/3
N2 - Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults. Chemotherapy improves survival indubitably in osteosarcoma; nevertheless, the concern is the stagnant progress since the last several decades. There are a handful of active agents and unresolved issues, especially in choosing the ideal chemotherapy regimen. The oncology community is in equipoise regarding the position of high-dose methotrexate (HDMTX), mandatory or adjunct. The choice of therapy becomes widely relevant, including in low- and middle-income countries (LMIC), where HDMTX administration brings additional complexities. Research into novel non-HDMTX-based protocols adapted to the available resources is pivotal in improving disease outcomes, especially in LMIC. The current review focuses on real-world challenges in decision-making and provides a comprehensive overview of the evolution of treatment protocols in LMIC.
AB - Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults. Chemotherapy improves survival indubitably in osteosarcoma; nevertheless, the concern is the stagnant progress since the last several decades. There are a handful of active agents and unresolved issues, especially in choosing the ideal chemotherapy regimen. The oncology community is in equipoise regarding the position of high-dose methotrexate (HDMTX), mandatory or adjunct. The choice of therapy becomes widely relevant, including in low- and middle-income countries (LMIC), where HDMTX administration brings additional complexities. Research into novel non-HDMTX-based protocols adapted to the available resources is pivotal in improving disease outcomes, especially in LMIC. The current review focuses on real-world challenges in decision-making and provides a comprehensive overview of the evolution of treatment protocols in LMIC.
UR - http://www.scopus.com/inward/record.url?scp=85122526378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122526378&partnerID=8YFLogxK
U2 - 10.1002/pbc.29540
DO - 10.1002/pbc.29540
M3 - Review article
C2 - 34971016
AN - SCOPUS:85122526378
SN - 1545-5009
VL - 69
JO - Medical and Pediatric Oncology
JF - Medical and Pediatric Oncology
IS - 3
M1 - e29540
ER -